RecruitingPhase 1NCT05101213
Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients
Studying Adenovirus infection in immunocompromised patients
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- M.D. Anderson Cancer Center
- Principal Investigator
- May Daher, MDM.D. Anderson Cancer Center
- Intervention
- Virus-specific Cytotoxic T-lymphocytes(biological)
- Enrollment
- 30 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2027
Study locations (1)
- M D Anderson Cancer Center, Houston, Texas, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05101213 on ClinicalTrials.govOther trials for Adenovirus infection in immunocompromised patients
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04364178Viral Specific T-Lymphocytes to Treat Adenovirus or CMVJessie L. Alexander
- RECRUITINGPHASE1NCT03425526Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related DiseaseM.D. Anderson Cancer Center
See all trials for Adenovirus infection in immunocompromised patients →